Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of hepatic low-density lipoprotein (LDL) receptors (LDLR), thereby, decreasing hepatocyte LDL-cholesterol (LDL-C) uptake. However, it is unknown whether PCSK9 has effects on atherogenesis that are independent of lip...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cardiovasc Res
Auteurs principaux: Tavori, Hagai, Giunzioni, Ilaria, Predazzi, Irene M., Plubell, Deanna, Shivinsky, Anna, Miles, Joshua, Devay, Rachel M., Liang, Hong, Rashid, Shirya, Linton, MacRae F., Fazio, Sergio
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
ORIGINAL ARTICLES
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4836631/
https://ncbi.nlm.nih.gov/pubmed/26980204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvw053
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires